Study 200170: A Rollover Study to Provide Continued Treatment With Eltrombopag

Trial Profile

Study 200170: A Rollover Study to Provide Continued Treatment With Eltrombopag

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 24 May 2017

At a glance

  • Drugs Eltrombopag (Primary)
  • Indications Thrombocytopenia
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline; Novartis Pharmaceuticals
  • Most Recent Events

    • 08 Aug 2016 Planned End Date changed from 1 Dec 2023 to 1 Jan 2024.
    • 08 Aug 2016 Planned primary completion date changed from 1 Dec 2023 to 1 Jan 2024.
    • 08 Aug 2016 This trial was completed in Ireland and Spain, according to the European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top